Lymphoma has a high recurrence rate. Lymphoma, i.e. malignant lymphoma, is a malignant disease of the hematologic system, including Hodgkin’s lymphoma and non-Hodgkin’s lymphoma, with non-Hodgkin’s lymphoma being more common. Malignant lymphoma is difficult to be cured completely, and can be treated with combination chemotherapy and molecular targeted therapy in order to put the disease into remission and thus prolong the survival period. During combination chemotherapy and/or molecular targeted therapy, the disease may relapse or progress. There are individual differences in the probability of relapse in patients with lymphoma, and it is also related to lymphoma staging. Some patients have advanced disease at the time of discovery, and these patients have a poorer prognosis and a higher probability of relapse after treatment. Among the lymphoma types, diffuse large B-cell lymphoma, angioimmunoblastic lymphoma, and condyloma are highly aggressive and have a higher probability of relapse after treatment. It is recommended that lymphoma patients should consult the hematology department in time, complete relevant examinations to clarify the typing, and formulate individualized treatment plans after evaluating their conditions.